{"entity":{"id":"nature-reviews-drug-discovery","kind":"journal","name":"Nature Reviews Drug Discovery","aka":["Nat Rev Drug Discov"],"tldr":"Nature Reviews Drug Discovery is Springer Nature's monthly review journal on how drugs are discovered and developed. Its News and Analysis pieces are the usual source for the pipeline, clinical success-rate and attrition statistics quoted about oncology development, so investors and policy analysts read it as much as scientists.","summary":"Nature Reviews Drug Discovery (Nat Rev Drug Discov) is a monthly review journal from Springer Nature, founded in 2002, covering how drugs are discovered and developed. It publishes commissioned reviews on drug targets and modalities, plus News and Analysis pieces tracking pipelines, approvals, clinical success rates and R&D costs. It is a major source for the 'probability of success' and pipeline-attrition statistics that frame oncology development, so its readers include drug developers, investors and policy analysts as well as scientists. Within OnCo it is linked from the Howard Kaufman biography, and a reader would use it for pipeline and success-rate data and for reviews of new therapeutic modalities.","asOf":"2026-09-09","links":[{"label":"Nature Reviews","url":"https://www.nature.com/nrd/about"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Springer Nature","url":"https://www.nature.com/nrd/","issn":"1474-1776","scope":"drug discovery","founded":2002,"matchNames":["Nature Reviews Drug Discovery","Nat Rev Drug Discov"]},"route":"/journals/nature-reviews-drug-discovery/","neighbours":{"person":[{"id":"howard-kaufman","kind":"person","name":"Howard L. Kaufman","route":"/people/howard-kaufman/"}],"paper":[{"id":"paper-depil-nat-rev-drug-discov","kind":"paper","name":"'Off-the-shelf' allogeneic CAR T cells: development and challenges","route":"/key-papers/paper-depil-nat-rev-drug-discov/"},{"id":"paper-upadhaya-nat-rev-drug-discov","kind":"paper","name":"Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape","route":"/key-papers/paper-upadhaya-nat-rev-drug-discov/"},{"id":"paper-goodnow-nat-rev-drug-discov","kind":"paper","name":"DNA-encoded chemistry: enabling the deeper sampling of chemical space","route":"/key-papers/paper-goodnow-nat-rev-drug-discov/"},{"id":"paper-bcl-2-cll-nat-rev-drug-discov-2017","kind":"paper","name":"From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors","route":"/key-papers/paper-bcl-2-cll-nat-rev-drug-discov-2017/"},{"id":"paper-bekes-nat-rev-drug-discov","kind":"paper","name":"PROTAC targeted protein degraders: the past is prologue","route":"/key-papers/paper-bekes-nat-rev-drug-discov/"}]}}